ArticleMarine drugs2014
Recognition of LPS by TLR4: potential for anti-inflammatory therapies.
Article in Marine drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Interaction between Genetic Risk Scores for reduced pulmonary function and smoking, asthma and endotoxin.Thorax · 2021Pooled it
- Bushen Huatan Formula Ameliorates Early Chronic Low-Grade Inflammation in Obese PCOS Via the TLR4/NF-κB Signaling Pathway: An Integrated Network Pharmacology and Experimental Study.Immunity, inflammation and disease · 2026Article
- Attenuation of LPS-induced inflammatory responses in J774A.1 macrophages by phenylpropanoids and ursane triterpenes from Lavandula coronopifolia Poir.Scientific reports · 2026Article
- Integrative 16S rRNA characterization, pan-genome, and immunoinformatics approaches for the design of a multi-epitope vaccine against Bacillus cereus, a foodborne pathogen.World journal of microbiology & biotechnology · 2026Article
- Exploring the mechanism of endothelial Pim-1 upregulation of tissue factor to initiate the hypercoagulable state in sepsis.Molecular medicine (Cambridge, Mass.) · 2026Article
- The Microbial Profile of Keloid Tissue: A Potential Biomarker for Lesion Activity.Biomedicines · 2026Article
- Immunoinformatics based design of a multiepitope vaccine targetingOpen medicine (Warsaw, Poland) · 2026Article
- Aster tataricus extract and its active compounds display a broad spectrum of antiviral activity in vitro and in vivo.Chinese medicine · 2025Article
- mTOR Inhibition limits LPS induced acute kidney injury and ameliorates hallmarks of cellular senescence.Scientific reports · 2025Article
- The role of TIR domain-containing proteins in bacterial defense against phages.Nature communications · 2024Article
- Intersecting Pathways: The Role of Metabolic Dysregulation, Gastrointestinal Microbiome, and Inflammation in Acute Ischemic Stroke Pathogenesis and Outcomes.Journal of clinical medicine · 2024Review
- Gut microbiota in MAFLD: therapeutic and diagnostic implications.Therapeutic advances in endocrinology and metabolism · 2024Review
- Anti-inflammatory effects of yeast-derived vacuoles on LPS-induced murine macrophage activation.Microbiology spectrum · 2023Article
- Periplaneta Americana Extract Ameliorates LPS-induced Acute Lung Injury Via Reducing Inflammation and Oxidative Stress.Current medical science · 2023Article
- Influence of Rural Environmental Factors in Asthma.Immunology and allergy clinics of North America · 2022Review
- Bacteriophage-ResistantViruses · 2021Article
- New Insights on End-Stage Renal Disease and Healthy Individual Gut Bacterial Translocation: Different Carbon Composition of Lipopolysaccharides and Different Impact on Monocyte Inflammatory Response.Frontiers in immunology · 2021Article
- Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies.Frontiers in cell and developmental biology · 2021Review
- Isolation of Anti-Inflammatory and Epithelium ReinforcingNutrients · 2020Article
- Recent Advances in Lipopolysaccharide Recognition Systems.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
LPS molecules of marine bacteria show structures distinct from terrestrial bacteria, due to the different environment that marine bacteria live in. Because of these different structures, lipid A molecules from marine bacteria are most often poor stimulators of the Toll-like receptor 4 (TLR4) pathway. Due to their low stimulatory potential, these lipid A molecules are suggested to be applicable as antagonists of TLR4 signaling in sepsis patients, where this immune response is amplified and unregulated. Antagonizing lipid A molecules might be used for future therapies against sepsis, therapies that currently do not exist. In this review, we will discuss these differences in lipid A structures and their recognition by the immune system. The modifications present in marine lipid A structures are described, and their potential as LPS antagonists will be discussed. Finally, since clinical trials built on antagonizing lipid A molecules have proven unsuccessful, we propose to also focus on different aspects of the TLR4 signaling pathway when searching for new potential drugs. Furthermore, we put forward the notion that bacteria probably already produce inhibitors of TLR4 signaling, making these bacterial products interesting molecules to investigate for future sepsis therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.